4//SEC Filing
Dambkowski Carl 4
Accession 0001104659-25-108652
CIK 0001974640other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 8:00 PM ET
Size
15.3 KB
Accession
0001104659-25-108652
Insider Transaction Report
Form 4
Dambkowski Carl
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-11-05$54.83/sh−2,200$120,626→ 288,293 total - Sale
Common Stock
2025-11-05$55.58/sh−5,607$311,637→ 282,686 total - Sale
Common Stock
2025-11-05$56.51/sh−678$38,314→ 282,008 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-05−8,060→ 153,565 totalExercise: $22.86Exp: 2033-12-18→ Common Stock (8,060 underlying) - Exercise/Conversion
Common Stock
2025-11-05$22.86/sh+8,060$184,252→ 292,793 total - Sale
Common Stock
2025-11-05$53.62/sh−2,300$123,326→ 290,493 total
Footnotes (6)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $53.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.24 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.25 to $56.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.31 to $56.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
Apogee Therapeutics, Inc.
CIK 0001974640
Entity typeother
Related Parties
1- filerCIK 0001983476
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 8:00 PM ET
- Size
- 15.3 KB